SCHEMBL10240614

SCHEMBL10240614

Cc1ccc(C2=CCN(C(C)C)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
KDM4E B2RXH2 1/20 0.50
NPC1 O15118 1/20 0.50
ALOX15 P16050 1/20 0.50
HTT P42858 1/20 0.50
RAB9A P51151 1/20 0.50
KCNH2 Q12809 3/20 0.46
HRH3 Q9Y5N1 1/20 0.46
ESRRB O95718 2/20 0.45
ESRRG P62508 2/20 0.45
ESR1 P03372 1/20 0.45
QDPR P09417 2/20 0.43
THRB P10828 2/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
SIGMAR1 Q99720 1/20 0.40
GAA P10253 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CHRNA7 P36544 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14565368 0.86 LMNA (0.48) LMNAKDM4ENPC1ALOX15HTT
SCHEMBL18965040 0.86 KDM4E (0.48) LMNAKDM4ENPC1ALOX15HTT
SCHEMBL13392447 0.86 KDM4E (0.48) LMNAKDM4ENPC1ALOX15HTT
SCHEMBL10057644 0.85 KCNH2 (0.60) LMNAKDM4ENPC1ALOX15HTT
SCHEMBL12878753 0.80 KDM4E (0.47) LMNAKDM4ENPC1ALOX15HTT
SCHEMBL4231835 0.80 KCNH2 (0.52) LMNAKDM4ENPC1ALOX15HTT
SCHEMBL21037761 0.79 LMNA (0.44) LMNAKDM4ENPC1ALOX15HTT
SCHEMBL22171245 0.78 ALOX15 (0.42) LMNAKDM4ENPC1ALOX15HTT
SCHEMBL18965280 0.78 CHRNB2 (0.49) LMNAKDM4ENPC1ALOX15HTT
SCHEMBL18965034 0.77 KDM4E (0.43) LMNAKDM4ENPC1ALOX15HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3480186-B1 NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT NOVMETAPHARMA CO LTD (KR) 2022-06-15 EP disclosed
EP-3459936-B1 NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) 2022-04-27 EP disclosed
EP-3480186-A1 NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT Kemimedi Co. Ltd (KR) 2019-05-08 EP disclosed
EP-3459936-A1 NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT Kemimedi Co. Ltd (KR) 2019-03-27 EP disclosed
US-8119654-B2 Indenoisoquinolinone analogs and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2012-02-21 US disclosed
US-20100179140-A1 INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2010-07-15 US disclosed
US-20100121049-A1 INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2010-05-13 US disclosed
US-7652028-B2 Indenoisoquinolinone analogs and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2010-01-26 US disclosed
US-20100004220-A1 Indenoisoquinolinone Analogs and Methods of Use Thereof INOTEK PHARMACEUTICALS CORPORATION 2010-01-07 US disclosed
US-20080214593-A1 TETRACYCLIC AMINO AND CARBOXAMIDO COMPOUNDS AND METHODS OF USE THEREOF JAGTAP PRAKASH 2008-09-04 US disclosed
WO-2008106619-A2 INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2008-09-04 WO disclosed
US-7381722-B2 Tetracyclic amino and carboxamido compounds and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2008-06-03 US disclosed
WO-2007025009-A2 INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2007-03-01 WO disclosed
US-20070049555-A1 Indenoisoquinolinone analogs and methods of use thereof INOTEK PHARMACEUTICALS CORPORATION (US) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214593-A1 TETRACYCLIC AMINO AND CARBOXAMIDO COMPOUNDS AND METHODS OF USE THEREOF GLS, AADAT, IAPP LMNA 4639/4885KDM4E 3097/4885NPC1 4489/4885
US-20070049555-A1 Indenoisoquinolinone analogs and methods of use thereof TNNI3, IDH2, GLS LMNA 407/4885KDM4E 2660/4885NPC1 3804/4885
US-20100121049-A1 INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF TNNI3, IDH2, GLS LMNA 407/4885KDM4E 2660/4885NPC1 3804/4885
US-20100004220-A1 Indenoisoquinolinone Analogs and Methods of Use Thereof TNNI3, IDH2, GLS LMNA 407/4885KDM4E 2660/4885NPC1 3804/4885
US-20100179140-A1 INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF TNNI3, IDH2, GLS LMNA 407/4885KDM4E 2660/4885NPC1 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.